Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 5, 2013, Pages 584-591

  Cortes, Jorge E ^a   Nicolini, Franck E ^b   Wetzler, Meir ^c   Lipton, Jeffrey H ^d   Akard, Luke ^e   Craig, Adam ^f   Nanda, Nisha ^g   Benichou, Annie Claude ^h   Leonoudakis, Janis ⁱ   Khoury, H Jean ^j   Hochhaus, Andreas ^k   Baccarani, Michele ^l   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e Indiana Blood and Marrow Transplantation   (United States)

^f TEVA PHARMACEUTICALS   (Israel)

^g ONYX PHARMACEUTICALS   (United States)

^h Stragen Services SAS   (France)

ⁱ Powered 4 Significance LLC   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k JENA UNIVERSITY HOSPITAL   (Germany)

^l UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Dasatinib; Homoharringtonine; Intolerance; Nilotinib; Resistance

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BUSULFAN; CHLORMETHINE; DASATINIB; ETOPOSIDE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; NILOTINIB; NITROSOUREA; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FAILURE FREE SURVIVAL; FATIGUE; FEBRILE BONE MARROW APLASIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

DASATINIB; HOMOHARRINGTONINE; INTOLERANCE; NILOTINIB; RESISTANCE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HARRINGTONINES; HUMANS; INFUSIONS, SUBCUTANEOUS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84884146561     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.020     Document Type: Article

References (35)

1. J.E. Cortes, M. Baccarani, and F. Guilhot Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study J Clin Oncol 28 2010 424 430
2. H. de Lavallade, J.F. Apperley, and J.S. Khorashad Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 2008 3358 3363
3. B.J. Druker, F. Guilhot, and S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
4. H. Kantarjian, N.P. Shah, and A. Hochhaus Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
5. G. Saglio, D.W. Kim, and S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
6. H.M. Kantarjian, N.P. Shah, and J.E. Cortes Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood 119 2012 1123 1129
7. R.A. Larson, D. Kim, and G. Rosti Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up [Abstract] J Clin Oncol 29 2011 6511
8. H. de Lavallade, J.S. Khorashad, and H.P. Davis Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation Blood 110 2007 2779 2780
9. H. Kantarjian, S. O'Brien, and E. Jabbour Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia J Clin Oncol 29 2011 3173 3178
10. H.M. Kantarjian, A. Hochhaus, and G. Saglio Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial Lancet Oncol 12 2011 841 851
11. J.F. Apperley Part II: management of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 2007 1116 1128
12. A. Hochhaus, M. Baccarani, and M. Deininger Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 2008 1200 1206
13. A. Hochhaus, H.M. Kantarjian, and M. Baccarani Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2007 2303 2309
14. H. Kantarjian, F. Giles, and L. Wunderle Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2006 2542 2551
15. H.M. Kantarjian, F. Giles, and N. Gattermann Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 2007 3540 3546
16. N.P. Shah, D.W. Kim, and H. Kantarjian Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib Haematologica 95 2010 232 240
17. M. Talpaz, N.P. Shah, and H. Kantarjian Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2006 2531 2541
18. S. Branford, Z. Rudzki, and S. Walsh High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 2002 3472 3475
19. M.E. Gorre, M. Mohammed, and K. Ellwood Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
20. N.P. Shah, J.M. Nicoll, and B. Nagar Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
21. E.K. Allan, T.L. Holyoake, and A.R. Craig Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells Leukemia 25 2011 985 994
22. L. Legros, S. Hayette, and F.E. Nicolini BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 21 2007 2204 2206
23. S. O'Brien, H. Kantarjian, and M. Keating Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase Blood 86 1995 3322 3326
24. A. Quintas-Cardama, H. Kantarjian, and G. Garcia-Manero Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy Cancer 109 2007 248 255
25. J. Cortes, J.H. Lipton, and D. Rea Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation Blood 120 2012 2573 2580
26. N. Nanda, C. Cortes, and J. Lipton Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survial compared to historical data [Abstract] Haematologica 96 2011 422 423
27. J. Cortes, A. Quintas-Cardama, and E. Jabbour The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk 11 2011 421 426
28. F.E. Nicolini, J.C. Chomel, and L. Roy The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge Clin Lymphoma Myeloma Leuk 10 2010 394 399
29. M.M. Coude, O. Luycx, and M.E. Cariou Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation Br J Haematol 157 2012 407 410
30. R.J. Garg, H. Kantarjian, and S. O'Brien The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up Blood 114 2009 4361 4368
31. F.J. Giles, E. Abruzzese, and G. Rosti Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy Leukemia 24 2010 1299 1301
32. A. Quintas-Cardama, H. Kantarjian, and D. Jones Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure Blood 109 2007 497 499
33. J.E. Cortes, H.M. Kantarjian, and N. Shah Subset analysis of response to treatment of chronic phase CML in a phase 1 study of ponatinib in refractory hematologic malignancies [Abstract] Blood (ASH Annual Meeting Abstracts) 118 2011 602
34. H.J. Khoury, J.E. Cortes, and H.M. Kantarjian Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure Blood 119 2012 3403 3412
35. J.E. Cortes, H. Kantarjian, and N.P. Shah Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2012 2075 2088